CRISPR

CRISPR1-exosc2

ID

ZDB-CRISPR-210813-5

Name

CRISPR1-exosc2

Previous Names

None

Target

exosc2 (1)

Sequence

5' - GAAACGTGTTTGTGAACCGC - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

The PAM site was "TGG" at the 3'end.

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
oi1	exosc2

Expression

Gene expression in Wild Types + CRISPR1-exosc2

No data available

Phenotype

Phenotype resulting from CRISPR1-exosc2

No data available

Phenotype of all Fish created by or utilizing CRISPR1-exosc2

Phenotype	Fish	Conditions	Figures
retina ab3-rho labeling amount, ameliorated	exosc2^oi1/oi1	chemical treatment: sirolimus	Fig. 4 from Yatsuka et al., 2020
eye decreased size, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 1, Fig. 4 from Yatsuka et al., 2020
spinal cord motor neuron amount, ameliorated	exosc2^oi1/oi1	chemical treatment: sirolimus	Fig. 4 from Yatsuka et al., 2020
whole organism decreased life span, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 1 from Yatsuka et al., 2020
whole organism ATP amount, ameliorated	exosc2^oi1/oi1	chemical treatment: sirolimus	Fig. 4 from Yatsuka et al., 2020
retina ab3-rho labeling decreased distribution, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 1, Fig. 4 from Yatsuka et al., 2020
lateral line myelin sheath degenerate, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 2 from Yatsuka et al., 2020
whole organism dead, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 1 from Yatsuka et al., 2020
whole organism ATP decreased amount, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 3, Fig. 4 from Yatsuka et al., 2020
whole organism GTP decreased amount, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 3, Fig. 4 from Yatsuka et al., 2020
whole organism CTP amount, ameliorated	exosc2^oi1/oi1	chemical treatment: sirolimus	Fig. 4 from Yatsuka et al., 2020
whole organism life span, ameliorated	exosc2^oi1/oi1	chemical treatment: sirolimus	Fig. 4 from Yatsuka et al., 2020
whole organism mbpb expression increased amount, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 3 from Yatsuka et al., 2020
lateral line myelin sheath deformed, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 2 from Yatsuka et al., 2020
swim bladder uninflated, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 1 from Yatsuka et al., 2020
whole organism CTP decreased amount, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 3, Fig. 4 from Yatsuka et al., 2020
spinal cord motor neuron decreased amount, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 2, Fig. 4 from Yatsuka et al., 2020
whole organism UTP decreased amount, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 3, Fig. 4 from Yatsuka et al., 2020
retina ab3-rho labeling position, ameliorated	exosc2^oi1/oi1	chemical treatment: sirolimus	Fig. 4 from Yatsuka et al., 2020
head size, ameliorated	exosc2^oi1/oi1	chemical treatment: sirolimus	Fig. 4 from Yatsuka et al., 2020
trunk bent, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 1 from Yatsuka et al., 2020
whole organism dead, abnormal	exosc2^oi1/oi1	chemical treatment: sirolimus	Fig. 4 from Yatsuka et al., 2020
head decreased size, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 1, Fig. 4 from Yatsuka et al., 2020
whole organism locomotory behavior decreased process quality, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 2 from Yatsuka et al., 2020
retina ab3-rho labeling decreased amount, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 1, Fig. 4 from Yatsuka et al., 2020
whole organism UTP amount, ameliorated	exosc2^oi1/oi1	chemical treatment: sirolimus	Fig. 4 from Yatsuka et al., 2020
whole organism mbpa expression increased amount, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 3 from Yatsuka et al., 2020
whole organism GTP amount, ameliorated	exosc2^oi1/oi1	chemical treatment: sirolimus	Fig. 4 from Yatsuka et al., 2020
whole organism decreased life span, abnormal	exosc2^oi1/oi1	chemical treatment: sirolimus	Fig. 4 from Yatsuka et al., 2020
eye decreased size, abnormal	exosc2^oi1/oi1	chemical treatment: sirolimus	Fig. 4 from Yatsuka et al., 2020
whole organism Ab1-exosc2 labeling absent, abnormal	exosc2^oi1/oi1	standard conditions	Fig. 1 from Yatsuka et al., 2020

Citations